On 21 May 2015, orphan designation (EU/3/15/1497) was granted by the European Commission to Prana Biotechnology UK Limited, United Kingdom, for 5,7-dichloro-2-dimethylaminomethyl-8-hydroxyquinoline hydrochloride for the treatment of Huntington's disease.

The sponsorship was transferred to Drug Development and Regulation S.L., Spain, in April 2019.

Key facts

Active substance
5,7-dichloro-2-dimethylaminomethyl-8-hydroxyquinoline hydrochloride
Disease / condition
Treatment of Huntington's disease
Date of first decision
EU designation number

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Drug Development and Regulation S.L.
Consell de Cent 375
08009 Barcelona
Tel. +34 9352 85385

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating